mRNA Cancer Vaccine Begins Trials for Lynch Syndrome Patients
Scientists are developing a revolutionary vaccine that could potentially prevent the development of bowel and ovarian cancer in a specific group of people. Clinical trials are scheduled to begin this summer to assess whether the injection can train the immune system to recognise and destroy pre-cancerous cells.
The primary focus of this research is individuals with Lynch Syndrome, an inherited genetic condition that increases the risk of bowel cancer by up to 80 percent. In the UK, an estimated 175,000 people have this syndrome, but only about 5 percent are aware of their condition.
The vaccine, coded mRNA-4194, is the result of a collaboration between the University of Oxford and the biotechnology company Moderna, with support from Cancer Research UK. Unlike traditional vaccines, this mRNA technology works like an instruction manual for the body.
Professor David Church, the lead researcher from the University of Oxford, explained that the vaccine is designed to make pre-cancerous cell mutations visible to the immune system. With the right stimulation, the immune system is expected to attack these abnormal cells before they develop into malignant tumours.
Lynch Syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is caused by changes in mismatch repair genes. Sufferers often show no early symptoms. Besides bowel cancer, the syndrome is also linked to a high risk of other cancer types.
Experts stress the importance of being vigilant about bowel habits, especially for those with a family history of cancer under the age of 50. Symptoms such as blood in the stool, changes in bowel habits lasting more than six weeks, and unexplained weight loss should be promptly consulted with medical professionals.
David Berman, Chief Development Officer at Moderna, stated that applying mRNA technology early in a patient’s journey aims to harness the immune system when its impact is greatest. If proven successful in Lynch Syndrome, the principle of training the immune system to recognise cancer-related changes could provide broad insights for preventing other types of cancer in the future.